Skip to content

XERIS + STRONGBRIDGECreating an Innovative Leader in Endocrinology and Rare Diseases

View Infographic

Xeris Pharmaceuticals, Inc. (“Xeris”) (Nasdaq: XERS) and Strongbridge Biopharma plc (“Strongbridge”) (Nasdaq: SBBP) have entered into a definitive agreement under which Xeris will acquire Strongbridge for stock and contingent value rights. Together they will create a diversified biopharmaceutical company with an enhanced growth profile, well-positioned for long-term product development and commercial success.

Press Releases

August 2, 2021

Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement

May 24, 2021

Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma


Rule 2.5 Announcement

Xeris - Rule 2.10 Announcement

Strongbridge – Rule 2.10 Announcement

Events and Presentations

Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc Investor Conference Call


Transaction Agreement

CVR Agreement

Xeris Pharmaceuticals SEC Filings

Strongbridge Biopharma SEC Filings

Joint Proxy Statement

Joint Proxy Statement Prospectus Dated July 28, 2021